The 19th European AIDS Conference (EACS 2023) held in Warsaw, Poland in October 2023 witnessed a groundbreaking announcement by Frontier Biotechnologies Inc. The latest clinical trial results of Aikening^®, a revolutionary treatment for people with HIV who have incomplete immune reconstitution, showcased remarkable success in significantly increasing CD4+ T-lymphocyte counts.

The clinical trial results presented at EACS 2023 have ignited new hope for individuals living with HIV and facing incomplete immune reconstitution. Aikening^®, developed by Frontier Biotechnologies Inc, has demonstrated its potential as a treatment regimen that can effectively boost CD4+ T-lymphocyte counts, a crucial indicator of immune system health.

Incomplete immune reconstitution is a significant challenge faced by people living with HIV, as it hampers their ability to fight off infections and diseases. The clinical trial results of Aikening^® have shown that this innovative treatment option can address this issue, offering a glimmer of hope to those in need.

Frontier Biotechnologies Inc is excited about the promising results, stating, We are thrilled to share the positive outcomes of our clinical trials for Aikening^® at the 19th European AIDS Conference. These results signify a major breakthrough in the field of HIV treatment, providing an alternative option for individuals with incomplete immune reconstitution. We believe Aikening^® has the potential to transform the lives of people living with HIV and restore their immune system function.

The clinical trial results of Aikening^® have sparked optimism among healthcare professionals and the HIV community. This intensive treatment regimen has the potential to fill a critical gap in current treatment options, offering new avenues for managing incomplete immune reconstitution and improving overall health outcomes for people living with HIV.